— Strengthened Balance Sheet in Support of Microbiome-Focused Clinical Development Programs — — Held Initial Type-B Multidisciplinary Meeting with FDA to Discuss Late-Stage Clinical Advancement for SYN-004 (ribaxamase) — — Conference Call Today, November 1, 2017, at 4:30 p.m. EDT — ROCKVILLE, Md., Nov. 1, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage […]
— Conference Call Scheduled for Wednesday, November 1, 2017 at 4:30 p.m. EDT — ROCKVILLE, Md., Oct. 25, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the Company intends to release its operational highlights
— SYN-004 (ribaxamase) Receives Breakthrough Therapy Designation from FDA for Prevention of CDI — — Three Ribaxamase Presentations to be Included at Infectious Disease Week™ (ID Week) 2017 — — Conference Call Today, August 3, 2017, at 8:30 a.m. EDT — ROCKVILLE, Md., Aug. 3, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage
— Conference Call Scheduled for Thursday, August 3, 2017 at 8:30 a.m. EDT — ROCKVILLE, Md., July 27, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the Company intends to release its operational highlights
— Allowance of Patent Provides Exclusive Method of Use Protection Until at Least 2034 — ROCKVILLE, Md., June 27, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the U.S. Patent and Trademark Office
— FDA Action Marks First Breakthrough Therapy Designation for Clinical Program Designed to Prevent Primary Clostridium difficile Infection — — Type-B Meeting Anticipated to Discuss Potential for Expedited Drug Development Strategy — ROCKVILLE, Md., May 11, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to
— Results from Phase 2b Proof-of-Concept Study Exploratory Endpoints Demonstrate Ribaxamase Protects and Preserves Gut Microbiome from Ceftriaxone-mediated Dysbiosis — — Two Ribaxamase and Two SYN-010 Presentations to be Included at Digestive Disease Week (DDW 2017) — — Conference Call Today, May 4, 2017, at 4:30 p.m. (EDT) — ROCKVILLE, Md., May 4, 2017 /PRNewswire/
— Study Results Further Support Advancement of SYN-005 into Clinical Trials for Treatment and Prevention of Pertussis — — Poster Presentations Planned for ECCMID and ESPID Conferences, Including Data from Prophylaxis Study — ROCKVILLE, Md., April 19, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome
— Company Highlights Clinical Successes of Late-stage Microbiome-focused Programs, Plans for Phase 3 Development — — Conference Call Today, March 2, 2017, at 4:30 p.m. (EST) — ROCKVILLE, Md., March 2, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health
Synthetic Biologics Reports 2016 Year End Operational Highlights and Financial Results Read More »
— Enrollment in SYN-010 Pivotal Trial Will Be Open to All IBS-C Patients — ROCKVILLE, Md., Jan. 18, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today confirmed plans to initiate a Phase 2b/3 adaptive pivotal
